Jefferies Raises TLRY Price Target to $2.00, Maintains 'Buy' Rating

Jefferies analyst Kaumil Gajrawala raised TLRY's price target from $1.50 to $2.00 while maintaining a 'Buy' rating. This represents a 33.33% increase and suggests potential growth and increased investor interest in Tilray Brands. The average target price for TLRY is $0.96, with a high estimate of $1.68 and a low estimate of $0.60, indicating a 29.49% downside from the current price of $1.36.

Jefferies analyst Kaumil Gajrawala recently raised the price target for Tilray Brands (NASDAQ:TLRY) from $1.50 to $2.00, while maintaining a 'Buy' rating. This marks a 33.33% increase and signals potential growth and heightened investor interest in the cannabis company. The new price target reflects Jefferies' view that the potential rescheduling of cannabis from Schedule I to Schedule III in the United States could significantly benefit Tilray [1].

The rescheduling, while not equivalent to full legalization, represents progress as Congress reviews bills related to banking, access, and reform in the cannabis sector. Jefferies identified Tilray as the "biggest potential beneficiary" of these regulatory developments, citing the company's strong financial health and moderate debt level [1]. Tilray's current assets exceed short-term obligations by 2.46x, indicating robust liquidity [1].

Additionally, Tilray Brands has been the subject of several recent research reports. Five analysts have given the stock a consensus rating of "Hold," with one analyst issuing a buy rating. The average 12-month target price among analysts is $1.9167, with a high estimate of $1.68 and a low estimate of $0.60. This suggests a 29.49% downside from the current price of $1.36 [2].

Tilray's CEO, Irwin D. Simon, purchased 165,000 shares at $0.61 per share, increasing his ownership to approximately $2.4 million. The company's latest earnings report revealed a positive EPS of $0.02, exceeding expectations despite falling short on revenue projections [2].

Shares of Tilray Brands have seen a significant boost in their stock price, jumping 17.7% amid reports that President Donald Trump is considering reclassifying marijuana as a less dangerous drug. This potential regulatory change has sparked interest across the cannabis industry [1]. Meanwhile, Tilray's stock has been trading below the $1 minimum required by Nasdaq for continued listing, and the company is exploring options to address this issue, including a potential reverse stock split [1].

References:
[1] https://www.investing.com/news/analyst-ratings/tilray-stock-price-target-raised-to-200-from-150-at-jefferies-93CH-4208417
[2] https://www.marketbeat.com/instant-alerts/tilray-brands-inc-nasdaqtlry-given-average-recommendation-of-hold-by-analysts-2025-08-23/